ISREC – Swiss Institute for Experimental Cancer Research

New cancer models could help personalize lymphoma treatments

Published:18.12.24 — Scientists at EPFL have developed "lymphomoids," a pioneering cancer model that preserves the structure and multicellular composition of lymphoma tumors in the lab. Lymphomoids offer an innovative way to test the efficacy of lymphoma treatments and better predict individual responses.

Enhancing breast cancer diagnosis and treatment

Published:19.07.24 — Addressing problems with diagnosing and treating breast cancer, scientists at EPFL have developed EMBER, a tool that integrates breast cancer transcriptomic data from multiple databases. EMBER can improve precision oncology by accurately predicting molecular subtypes and therapy responses.

Antibody-peptide inhibitor conjugates: a new path for cancer therapy

Published:03.06.24 — Cancer treatments often struggle with balancing efficacy and side effects. A new study by EPFL scientists offers a promising solution using antibody-peptide inhibitor conjugates to target specific cell types and block the activity of cancer-promoting enzymes called cathepsins.